{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:35Z","timestamp":1793132195778,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41375-024-02330-7","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:07:00Z","timestamp":1720541220000},"page":"1831-1838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-1472","authenticated-orcid":false,"given":"Martin H.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-2353","authenticated-orcid":false,"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2330_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141:1954\u201370.","journal-title":"Blood"},{"key":"2330_CR2","unstructured":"US Food and Drug Administration. Highlights of prescribing information: JAKAFI\u00ae (ruxolitinib). 2021. https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf Accessed 22 November 2023."},{"key":"2330_CR3","unstructured":"US Food and Drug Administration. Highlights of prescribing information: INREBIC\u00ae (fedratinib). 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212327s004lbl.pdf Accessed 22 November 2023."},{"key":"2330_CR4","unstructured":"European Medicines Agency. Summary of product characteristics: JAKAVI\u00ae (ruxolitinib). 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jakavi-epar-product-information_en.pdf Accessed 22 November 2023."},{"key":"2330_CR5","unstructured":"European Medicines Agency. Summary of product characteristics: INREBIC\u00ae (fedratinib). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf Accessed 22 November 2023."},{"key":"2330_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"2330_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015;1:643.","journal-title":"JAMA Oncol"},{"key":"2330_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian J, Jourdan E, Silver RT, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020;95:594\u2013603.","journal-title":"Am J Hematol"},{"key":"2330_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"2330_CR10","unstructured":"US Food and Drug Administration. Highlights of prescribing information: VONJO\u00ae (pacritinib). 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208712s000lbl.pdf Accessed 22 November 2023."},{"key":"2330_CR11","unstructured":"US Food and Drug Administration. Highlights of prescribing information: OJJAARA\u00ae (momelotinib). 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA-PI-PIL.PDF Accessed 22 November 2023."},{"key":"2330_CR12","unstructured":"European Medicines Agency. Summary of product characteristics: OMJJARA\u00ae (momelotinib). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omjjara-epar-product-information_en.pdf Accessed 12 April."},{"key":"2330_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Harrison CN, Mesa RA, Kiladjian J-J, Vannucchi AM, Verstovsek S. Anemia in myelofibrosis: Current and emerging treatment options. Crit Rev Oncol Hematol. 2022;180:103862.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2330_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","volume":"102","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S. How I manage anemia related to myelofibrosis and its treatment regimens. Ann Hematol. 2023;102:689\u201398.","journal-title":"Ann Hematol"},{"key":"2330_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","volume":"95","author":"I Appelmann","year":"2016","unstructured":"Appelmann I, Kreher S, Parmentier S, Wolf H-H, Bisping G, Kirschner M, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016;95:707\u201318.","journal-title":"Ann Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02330-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02330-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:03:29Z","timestamp":1722265409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02330-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2330"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02330-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK: Received consultancy, honoraria, Board of Directors or advisory board\/committee membership, travel\/accommodation support and\/or research funding from AbbVie, Alexion, AOP Orphan Pharmaceuticals, AOP Pharma, Ariad, Bayer, Bedrock, Bristol Myers Squibb\/Celgene, Celgene, CTI BioPharma, Geron, GlaxoSmithKline, Imago Bioscience, iOMEDICO, Incyte, Janssen, Kartos, MPN Hub, MSD, Novartis, Pfizer, PharmaEssentia, Protagonist, Roche, Sierra Oncology. Patent issued for a bromodomain and extraterminal motif (BET) inhibitor and royalties received from RWTH Aachen University; PB: Received honoraria and\/or research funding from AbbVie, Blueprint, BMS, Cogent, CTI BioPharma, Disc, Geron, GlaxoSmithKline, Incyte, Ionis, Janssen, Jubilant, Kartos, Karyopharm, Morphic, MorphoSys, Novartis, PharmaEssentia, Sumitomo, and Telios. ME: Received advisory board and speakers bureau membership, research funding and\/or honoraria from Bristol Myers Squibb, Gad Medical, GlaxoSmithKline, and Novartis. VG: Received consulting fees, honoraria, Board of Directors or advisory board\/committee membership and\/or data Safety Monitoring Board participation from AbbVie, Bristol Myers Squibb\/Celgene, Constellation Pharmaceuticals, CTI BioPharma, GlaxoSmithKline, Novartis, Pfizer, Sierra Oncology, SMP Oncology, Roche, Pfizer, and Sierra Oncology. Received travel support for European Hematology Association (EHA) 2023 (invited talk at a GlaxoSmithKline-sponsored myeloproliferative neoplasms education session). JJK: Received consulting fees and\/or Board of Directors or advisory committee membership from AbbVie, AOP Health, AOP Orphan Pharmaceuticals, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, and PharmaEssentia. JM: Received consulting fees, Board of Directors or advisory committee membership, research funding, honoraria and\/or consulting or advisory committee participation from AbbVie, Bristol Myers Squibb\/Celgene, Constellation Pharmaceuticals, CTI BioPharma, Galecto, Geron, GlaxoSmithKline, Imago Biosciences, Incyte, Janssen, Kartos Therapeutics, Karyopharm Therapeutics, Merck, MorphoSys, Novartis, Pfizer, PharmaEssentia, Prelude Therapeutics, Roche, and Sierra Oncology. VM: Received honoraria from GlaxoSmithKline. FP: Received consultancy, honoraria, and\/or research funding from AbbVie, AOP Orphan Pharmaceuticals, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Kyowa Kirin, MEI, Novartis, Roche, Sierra Oncology, and Sumitomo. CH: Received honoraria, research funding and\/or speakers bureau membership from AbbVie, AOP, Bristol Myers Squibb, CTI BioPharma, Galecto, GlaxoSmithKline, MorphoSys, and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}